Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:TRML

Tourmaline Bio Q2 2024 Earnings Report

Tourmaline Bio logo
ProfileEarnings HistoryForecast

Tourmaline Bio EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Tourmaline Bio's Q2 2024 Press ReleasePress Release
(8-K)
Tourmaline Bio's Q2 2024 Quarterly ReportQuarterly Report
(10-Q)

Tourmaline Bio Earnings Headlines

Tourmaline Bio acquisition completed by Novartis
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tourmaline-bio-acquisition-completed-by-novartis/ar-AA1PmVFi
Novartis announces expiration of Tourmaline Bio tender offer
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/novartis-announces-expiration-of-tourmaline-bio-tender-offer/ar-AA1PlhGR
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 9 at 1:00 AM  |  American Alternative (Ad)
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
October 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251006398102/en/tourmaline-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-tourmaline-bio-inc.---trml/
Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90
September 30, 2025  |  msn.comhttps://www.msn.com/en-us/general/general/tourmaline-bio-trml-price-target-decreased-by-14-70-to-48-90/ar-AA1NA13M
Novartis announces commencement of tender offer to acquire Tourmaline Bio
September 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/29/3157623/0/en/novartis-announces-commencement-of-tender-offer-to-acquire-tourmaline-bio.html
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile
Earnings Tools